2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
250
Lymphoma
128
Leukemia, Myeloid, Acute
103
Lymphoma, Non-Hodgkin
98
Precursor Cell Lymphoblastic Leukemia-Lymphoma
93
Neoplasms, Plasma Cell
91
Myelodysplastic Syndromes
91
Leukemia
79
Hodgkin Disease
78
Lymphoma, Large B-Cell, Diffuse
66
Leukemia, Lymphocytic, Chronic, B-Cell
65
Lymphoma, Mantle-Cell
59
Lymphoma, Follicular
57
Neuroblastoma
44
Burkitt Lymphoma
44
Lymphoma, Large-Cell, Immunoblastic
40
Lymphoma, B-Cell, Marginal Zone
37
Recurrence
34
Myeloproliferative Disorders
32
Hematologic Neoplasms
32
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
30
Immunoglobulin Light-chain Amyloidosis
29
Leukemia, Myeloid, Accelerated Phase
25
Leukemia, Myeloid, Chronic-Phase
24
Congenital Abnormalities
24
Leukemia, Myelomonocytic, Chronic
23
Graft vs Host Disease
23
Dendritic Cell Sarcoma, Interdigitating
21
Waldenstrom Macroglobulinemia
20
Melanoma
20
Interventions
Etoposide
3
Carboplatin
3
Vincristine
2
Topotecan
1
Platinum Compounds
1
Melphalan
1
Lasers, Semiconductor
1
Lasers
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Eye Enucleation
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Cryotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Retinal Neoplasms
×
Melphalan
×
Clear all
NCT02866136
2025-11-24
RETINO2011
Institut Curie
Phase 2
Active not recruiting
133 enrolled